Abbott to Acquire Exact Sciences, a Leader in Large and Fast-Growing Cancer Screening and Precision Oncology Diagnostics Segments
Abbott will acquire Exact Sciences for about $21 billion, gaining a foothold in fast-growing cancer screening and precision oncology diagnostics. The deal values Exact at $105 per share and aims to expand access to early cancer detection and personalized treatment guidance, including products like Cologuard and Oncotype DX. The integration is intended to accelerate innovation and improve monitoring of cancer from detection to management.

Overview of the deal

Abbott and Exact Sciences announced a definitive agreement under which Abbott will acquire Exact Sciences. Exact Sciences shareholders will receive $105 per common share, representing an equity value of approximately $21 billion. The combined company is positioned to lead in large, fast-growing cancer diagnostics markets and broaden access to transformative tests.

Key product lines and capabilities

Strategic rationale

The combination aims to accelerate innovation in cancer diagnostics, expand patient access to life-changing tests, and enable earlier detection and more effective treatment decisions. The deal is described as immediately accretive to Abbott’s revenue growth and gross margin, with potential to transform cancer care by focusing on early detection and ongoing monitoring.

Exact Sciences focuses on early cancer detection and supports personalized treatments through its comprehensive product portfolio, including screening, precision oncology, and genetic testing leadership.

Impact and next steps

Author summary

Abbott’s planned acquisition of Exact Sciences positions the company to lead in cancer diagnostics by combining broad screening and precision oncology capabilities with Abbott’s global scale and access to care networks, aiming to improve early detection and treatment outcomes for millions of people.

more

Urban Milwaukee Urban Milwaukee — 2025-11-20

More News